Back to journals
Academic JournalOpen Access

EClinicalMedicine

6 Papers Indexed in Blossom

Data updated

Research Footprint

EClinicalMedicine has 6 tracked papers indexed in Blossom (2020–2025) from 68 authors, most often covering Psilocybin, Ketamine and Esketamine, across Depressive Disorders, Major Depressive Disorder (MDD) and Safety & Risk Management.

Published Papers

Open Accessindividual

Investigational psilocybin treatment for post-traumatic stress disorder: a qualitative study of participant experience, trauma engagement, and differences from standard treatment

This qualitative sub-study (n=21) nested within a Phase II trial found that psilocybin treatment enabled participants with PTSD to engage with trauma-related material both directly and indirectly through affective, somatic, and self-transcendent experiences, contrasting with standard treatments that require direct confrontation with trauma memories.

Published
Journal
EClinicalMedicine
Authors
Modlin, N. L., Williamson, V., Goodwin, G. M., Malievskaia, E., Atli, M., Elek, Z., Gaillard, A., Koelpin, D., Cleare, A., Agrawal, M., Yehuda, R., Kirlic, N., Rucker, J.
Open Accessindividual

Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial

This double-blind randomised clinical trial (n=37) found that a single dose of psilocybin (25mg) with brief psychotherapy did not significantly reduce alcohol relapse rates or consumption compared to placebo in patients with alcohol use disorder (AUD) at 4-week or 6-month follow-up, though psilocybin participants reported additional reductions in craving and temptation to drink, suggesting larger trials are needed to evaluate this approach for severely affected patients.

Published
Journal
EClinicalMedicine
Authors
Rieser, N. M., Bitar, R., Halm, S., Rossgoderer, C., Gubser, L. P., Thévenaz, M., Kreis, Y., Von Rotz, R., Nordt, C., Visentini, M., Moujaes, F., Engeli, E. J. E., Ort, A., Seifritz, E., Vollenweider, F. X., Herdener, M., Preller, K. H.
Open Accessindividual

Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial

This 6-month follow-up of a Phase II, double-blind, randomised controlled trial (n=59) finds sustained improvements in depressive symptoms for both psilocybin therapy (PT) and escitalopram treatment (ET) for moderate-to-severe major depressive disorder (MDD). PT shows greater improvements in psychosocial functioning, meaning in life, and psychological connectedness compared to ET at the 6-month follow-up.

Published
Journal
EClinicalMedicine
Authors
Erritzoe, D., Barba, T., Greenway, K. T., Murphy-Beiner, A., Murphy, R., Martell, J., Giribaldi, B., Timmermann, C., Baker-Jones, M., Nutt, D. J., Weiss, B., Carhart-Harris, R. L.
Open Accessmeta

Ketamine for the treatment of major depression: a systematic review and meta-analysis

This systematic review and meta-analysis (n=3299) investigated the efficacy of ketamine for depression by analysing 49 randomised controlled trials (RCTs). The study found that racemic ketamine had numerically greater effects on depression severity, response, and remission rates compared to esketamine. Higher doses were more effective than low doses, with differences evident in initial effects, ongoing treatment, and lasting effects post-final dose.

Published
Journal
EClinicalMedicine
Authors
Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C. A., Vazquez, G. H., Loo, C.
Open Accessindividual

Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial

This double-blind placebo-controlled study (n=56) found that one psilocybin-assisted therapy (16mg/70kg, 2 prep + 3 integration meetings) session significantly reduced depressive symptoms (MADRS & BDI) in those suffering from a major depressive disorder (MDD, n=26). Fourteen days after the intervention, 54% of those in the psilocybin group met remission criteria (<10 on MADRS).

Published
Journal
EClinicalMedicine
Authors
Schindowski, E. M., Jungwirth, J., Schuldt, A., Rieser, N. M., Zahoranszky, K., Seifritz, E., Nowak, A., Nowak, P., Jäncke, L., Preller, K. H., Vollenweider, F. X., van Rotz, R.
Open Accessindividual

Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: An open-label safety and feasibility pilot study

This open-label feasibility study (n=17) showed that psilocybin-assisted group therapy (21-25mg/70kg) was safe and effective for the treatment of demoralization in older long-term AIDS survivors.

Published
Journal
EClinicalMedicine
Authors
Anderson, B. T., Danforth, A. L., Daroff, R., Stauffer, C., Ekman, E., Agin-Liebes, G. I., Trope, A., Boden, M. T., Dilley, J., Mitchell, J., Woolley, J. D.

Quick Facts

Papers Indexed
6
h-Index
99
Open Access
Yes
Publisher
Elsevier
Country
United Kingdom
Website
Visit